Patients who received BL1332 showed numerically greater pain relief across the analysis 72 hours after surgery, the eye-health company said. The treatment was well tolerated.
Bausch + Lomb is completing its analysis of the data and plans to discuss the findings with the Food and Drug Administration, including potential plans for a Phase 3 trial.

Comments (0)
No comments yet. Be the first!